Effects of imperatorin on nicotine-induced anxiety- and memory-related responses and oxidative stress in mice

Physiology and Behavior

Volumn 122, Issue , 2013, Pages 46-55

  Budzynska, Barbara ^a   Boguszewska Czubara, Anna ^a   Kruk Slomka, Marta ^a   Skalicka Wozniak, Krystyna ^a   Michalak, Agnieszka ^a   Musik, Irena ^a   Biala, Grazyna ^a   Glowniak, Kazimierz ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Angelica officinalis; Anxiety; Imperatorin; Memory; Mice; Oxidative stress

Indexed keywords

GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; MALONALDEHYDE; NICOTINE; PENTOSALEN; SUPEROXIDE DISMUTASE;

ANGELICA ARCHANGELICA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; BRAIN LEVEL; COGNITION; CONTROLLED STUDY; COUNTER CURRENT CHROMATOGRAPHY; DRUG EFFECT; ENZYME ACTIVITY; HIPPOCAMPUS; MALE; MAZE TEST; MEMORY; MEMORY ACQUISITION; MEMORY CONSOLIDATION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PASSIVE AVOIDANCE; PREFRONTAL CORTEX; PRIORITY JOURNAL; REPEATED DRUG DOSE;

ANGELICA OFFICINALIS; ANXIETY; IMPERATORIN; MEMORY; MICE; OXIDATIVE STRESS;

ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; COGNITION; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; HIPPOCAMPUS; MALE; MALONDIALDEHYDE; MEMORY; MICE; NICOTINE; OXIDATIVE STRESS; PREFRONTAL CORTEX; PSORALENS; SUPEROXIDE DISMUTASE;

EID: 84884148727     PISSN: 00319384     EISSN: 1873507X     Source Type: Journal    
DOI: 10.1016/j.physbeh.2013.08.019     Document Type: Article

References (83)

1. Thorne S.L., Malarcher A., Maurice E., Caraballo R. Cigarette smoking among adults-United States, 2007. JAMA 2009, 301(4):373-375.
2. Stolerman I.P., Jarvis M.J. The scientific case that nicotine is addictive. Psychopharmacology (Berl) 1995, 117:2-10.
3. Fiore M.C., Hatsukami D.K., Baker T.B. Effective tobacco dependence treatment. JAMA 2002, 288:1768-1771.
4. Herman A.I., Sofuoglu M. Comparison of available treatments for tobacco addiction. Curr Psychiatry Rep 2010, 12:433-440.
5. Levin E.D. Nicotinic receptor subtypes and cognitive function. J Neurobiol 2002, 53:633-640.
6. Levin E.D., Petro A., Rezvani A.H., Pollard N., Christopher N.C., Strauss M., et al. Nicotinic α7- or β2-containing receptor knockout: effects on radial-arm maze learning and long-term nicotine consumption in mice. Behav Brain Res 2009, 196:207-213.
7. Sarter M., Parikh V., Howe W.M. nAChR agonist-induced cognition enhancement: integration of cognitive and neuronal mechanisms. Biochem Pharmacol 2009, 78:658-667.
8. Sofuoglu M. Cognitive enhancement as a pharmacotherapy target for stimulant addiction. Addiction 2010, 105:38-48.
9. File S.E., Cheeta S., Kenny P.J. Neurobiological mechanisms by which nicotine mediates different types of anxiety. Eur J Pharmacol 2000, 393:231-236.
10. Marubio L.M., Arroyo-Jimenez M.D.M., Cordero-Erausquin M., Léna C., Le Novère N., de Kerchove d'Exaerde A., et al. Reduced antinociception in mice lacking neuronal nicotinic receptor subunits. Nature 1999, 398:805-810.
11. Hayase T. Differential effects of TRPV1 receptor ligands against nicotine-induced depression-like behaviors. BMC Pharmacol 2011, 11:6.
12. Wonnacott S. Presynaptic nicotinic ACh receptors. Trends Neurosci 1997, 20:92-98.
13. Dani J.A., De Biasi M. Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav 2001, 70:439-446.
14. Malin D.H. Nicotine dependence. Studies with a laboratory model. Pharmacol Biochem Behav 2001, 70:551-559.
15. Yildiz D. Nicotine, its metabolism and an overview of its biological effects. Toxicon 2004, 43:619-632.
16. Baek N.I., Ahn E.M., Kim H.Y., Park Y.D. Furanocoumarins from the root of Angelica dahurica. Arch Pharm Res 2000, 23:467-470.
17. Murray R.D.H., Mendez J., Brown S.A. The natural coumarins: occurrence. Chemistry and Biochemistry 1982, Wiley, New York.
18. Abed M.J., de las Heras B., Silvan A.M., Pascual R., Bermejo P., Rodriquez B., et al. Effects of furocoumarins from Cachrys trifida on some macrophage functions. J Pharm Pharmacol 2001, 53:1163-1168.
19. Ban H.S., Lim S.S., Suzuki K., Jung S.H., Lee S., Lee Y.S., et al. Inhibitory effects of furanocoumarins isolated from the roots of Angelica dahurica on prostaglandin E2 production. Planta Med 2003, 69:408-441.
20. Garcia-Argaez A.N., Ramirez Apan T.O., Parra Delgado H., Velazquez G., Martinez-Vazquez M. Anti-inflammatory activity of coumarins from Decatropis bicolor on TPA ear mice model. Planta Med 2000, 66:279-281.
21. Kawaii S., Tomono Y., Ogawa K., Sugiura M., Yano M., Yoshizawa Y., et al. Antiproliferative effect of isopentenylated coumarins on several cancer cell lines. Anticancer Res 2001, 21:1905-1911.
22. Łuszczki J.J., Głowniak K., Czuczwar S.J. Time-course and dose-response relationships of imperatorin in the mouse maximal electroshock seizure threshold model. Neurosci Res 2007, 59:18-22.
23. He J.Y., Zhang W., He L.C., Cao Y.X. Imperatorin induces vasodilatation possibly via inhibiting voltage dependent calcium channel and receptor-mediated Ca2+ influx and release. Eur J Pharmacol 2007, 573:170-175.
24. Deng S., Chen S.N., Yao P., Nikolic D., van Breemen R.B., Bolton J.L., et al. Serotonergic activity-guided phytochemical investigation of the roots of Angelica sinensis. J Nat Prod 2006, 69:536-541.
25. Choi S.Y., Ahn E.M., Song M.C., Kim D.W., Kang J.H., Kwon O.S., et al. In vitro GABA-transaminase inhibitory compounds from the root of Angelica dahurica. Phytother Res 2005, 19:839-845.
26. Fylaktakidou K.C., Hadjipavlou-Litina D.J., Litinas K.E., Nicolaides D.N. Natural and synthetic coumarin derivatives with anti-inflammatory/antioxidant activities. Curr Pharm Des 2004, 10:3813-3833.
27. Kontogiorgis C.A., Savvoglou K., Hadjipavlou-Litina D.J. Antiinflammatory and antioxidant evaluation of novel coumarin derivatives. J Enzyme Inhib Med Chem 2006, 21:21-29.
28. Vianna D.R., Bubols G., Meirelles G., Silva B.V., da Rocha A., Lanznaster M., et al. Evaluation of the antioxidant capacity of synthesized coumarins. Int J Mol Sci 2012, 13:7260-7270.
29. Valko M., Leibfritz D., Moncol J., Cronin M.T., Mazur M., Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007, 39:44-84.
30. Gumustekin K., Altinkaynak K., Timur H., Taysi S., Oztasan N., Polat M.F., et al. Vitamin E but not Hippophea rhamnoides L. prevented nicotine-induced oxidative stress in rat brain. Hum Exp Toxicol 2003, 22:425-431.
31. Gumustekin K., Taysi S., Alp H.H., Aktas O., Oztasan N., Akcay F., et al. Vitamin E and Hippophea rhamnoides L. extract reduce nicotine-induced oxidative stress in rat heart. Cell Biochem Funct 2010, 28:329-333.
32. Taupin P. A dual activity of ROS and oxidative stress on adult neurogenesis and Alzheimer's disease. Cent Nerv Syst Agents Med Chem 2010, 10:16-21.
33. Walton N.M., Shin R., Tajinda K., Heusner C.L., Kogan J.H., Miyake S., et al. Adult neurogenesis transiently generates oxidative stress. PLoS One 2012, 7(4).
34. Glade M.J. Oxidative stress and cognitive longevity. Nutrition 2010, 26:595-603.
35. Phillis J.W., Horrocks L.A., Farooqui A.A. Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders. Brain Res Rev 2006, 52:201-243.
36. Kirkman H.N., Gaetani G.F. Mammalian catalase: a venerable enzyme with new mysteries. Trends Biochem Sci 2007, 32:44-50.
37. Drevet J.R. The antioxidant glutathione peroxidase family and spermatozoa: a complex story. Mol Cell Endocrinol 2006, 250:70-79.
38. Bayir H., Kagan V.E., Clark R.S., Janesko-Feldman K., Rafikov R., Huang Z., et al. Neuronal NOS-mediated nitration and inactivation of manganese superoxide dismutase in brain after experimental and human brain injury. J Neurochem 2007, 101:168-181.
39. Fattman C.L., Schaefer L.M., Oury T.D. Extracellular superoxide dismutase in biology and medicine. Free Radic Biol Med 2003, 35:236-256.
40. Wu G., Fang Y.Z., Yang S., Lupton J.R., Turner N.D. Glutathione metabolism and its implications for health. J Nutr 2004, 134:489-492.
41. Lykkesfeldt J. Malondialdehyde as biomarker of oxidative damage to lipids caused by smoking. Clin Chim Acta 2007, 380:50-58.
42. Biala G., Kruk M., Budzynska B. Effects of the cannabinoid receptor ligands on anxiety-related effects of d-amphetamine and nicotine in the mouse elevated plus maze test. J Physiol Pharmacol 2009, 60:113-122.
43. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 1986, 92:180-185.
44. Venault P., Chapouthier G., de Carvalho L.P., Simiand J., Morre M., Dodd R.H., et al. Benzodiazepine impairs and beta-carboline enhances performance in learning and memory tasks. Nature 1986, 321:864-866.
45. Allami N., Javadi-Paydar M., Rayatnia F., Sehhat K., Rahimian R., Norouzi A., et al. Suppression of nitric oxide synthesis by L-NAME reverses the beneficial effects of pioglitazone on scopolamine-induced memory impairment in mice. Eur J Pharmacol 2011, 650:240-248.
46. Borowicz K.K., Gasior M., Kleinrok Z., Czuczwar S.J. The non-competitive AMPA/kainate receptor anatgonist, GYKI 52466, potentiates the anticonvulsant activity of conventional antiepileptics. Eur J Pharmacol 1995, 281:319-326.
47. Hiramatsu M., Murasawa H., Nabeshima T., Kameyama T. Effects of U-50,488H on scopolamine-, mecamylamine and dizocilpine-induced learning and memory impairment in rats. J Pharmacol Exp Ther 1998, 284:858-867.
48. Javadi-Paydar M., Zakeri M., Norouzi A., Rastegar H., Mirazi N., Dehpour A. Involvement of nitric oxide in granisetron improving effect on scopolamine-induced memory impairment in mice. Brain Res Rev 2012, 1429:61-71.
49. Budzynska B., Kruk-Slomka M., Skalicka-Wozniak K., Biala G., Glowniak K. The effects of imperatorin on anxiety and memory-related behavior in male Swiss mice. Exp Clin Psychopharmacol 2012, 20:325-332.
50. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
51. Paglia D.E., Valentine W.N. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967, 70:158-169.
52. Goldberg D.M., Spooner R.J. Methods of enzymatic analysis 1983, 258-265. Verlog Chemie, Deerfield Beach. 3rd ed. H.V. Bergmeyen (Ed.).
53. Chimakurthy J., Talasila M. Effects of curcumin on pentylenetetrazole-induced anxiety-like behaviors and associated changes in cognition and monoamine levels. Psychol Neurosci 2010, 3:239-244.
54. Hogle J.M., Kaye J.T., Curtin J.J. Nicotine withdrawal increases threat-induced anxiety but not fear: neuroadaptation in human addiction. Biol Psychiatry 2010, 68:719-725.
55. Domier C.P., Monterosso J.R., Brody A.L., Simon S.L., Mendrek A., Olmstead R., et al. Effects of cigarette smoking and abstinence on Stroop task performance. Pschopharmacology 2007, 195:1-9.
56. Kenney J.W., Gould T.J. Nicotine enhances context learning but not context-shock associative learning. Behav Neurosci 2008, 122:1158-1165.
57. Kenney J.W., Gould T.J. Modulation of hippocampus-dependent learning and synaptic plasticity by nicotine. Mol Neurobiol 2008, 38:101-121.
58. Kruk M., Tendera K., Biała G. Memory-related effects of cholinergic receptor ligands in mice as measured by the elevated plus maze test. Pharmacol Rep 2011, 63:1372-1382.
59. Brioni J.D., O'Neill A.B., Kim D.J.B., Decker M.W. Nicotine receptor agonists exhibit anxiolytic-like effects on the elevated plus-maze test. Eur J Pharmacol 1993, 238:1-8.
60. Ledwozyw A., Michalak J., Stepień A., Kadziołka A. The relationship between plasma triglycerides, cholesterol, total lipids and lipid peroxidation products during human atherosclerosis. Clin Chim Acta 1986, 155:275-283.
61. Irvine E.E., Cheeta S., File S.E. Development of tolerance to nicotine's anxiogenic effect in the social interaction test. Brain Res 2001, 894:95-100.
62. Ouagazzal A.M., Kenny P.J., File S.E. Modulation of behaviour on trials 1 and 2 in the elevated plus-maze test of anxiety after systemic and hippocampal administration of nicotine. Psychopharmacology 1999, 144:54-60.
63. Sharifzadeh M., Tavasoli M., Naghdi N., Ghanbari A., Amini M., Roghani A. Post-training intrahippocampal infusion of nicotine prevents spatial memory retention deficits induced by the cyclo-oxygenase-2-specific inhibitor celecoxib in rats. J Neurochem 2005, 95:1078-1090.
64. Kenney J.W., Adoff M.D., Wilkinson D.S., Gould T.J. The effects of acute, chronic, and withdrawal from chronic nicotine on novel and spatial object recognition in male C57BL/6J mice. Psychopharmacology (Berl) 2011, 353-365.
65. Picciotto M.R., Brunzell D.H., Caldarone B.J. Effect of nicotine and nicotinic receptors on anxiety and depression. Neuroreport 2002, 13:1097-1106.
66. Varani A.P., Balerio G.N. GABA(B) receptors involvement in the effects induced by nicotine on anxiety-related behaviour in mice. Pharmacol Res 2012, 65:507-513.
67. Dawson G.R., Tricklebank M.D. Use of the elevated plus maze in the search for novel anxiolytic agents. Trends Pharmacol Sci 1995, 16:33-36.
68. Pellow S., Chopin P., File S.E., Briley M. Validation of open: closed arm entries in an elevated plus maze as a measure of anxiety in the rats. J Neurosci Methods 1985, 14:149-167.
69. Bergendorff O., Dekermendjian K., Nielsen M., Shan R., Witt R., Ai J., et al. Furanocoumarins with affinity to brain benzodiazepine receptors in vitro. Phytochemistry 1997, 44:1121-1124.
70. Loscertales M., Rose S.P., Daisley J.N., Sandi C. Piracetam facilitates long-term memory for a passive avoidance task in chicks through a mechanism that requires a brain corticosteroid action. Eur J Neurosci 1998, 10:2238-2243.
71. Leiser S.C., Bowlby M.R., Comery T.A., Dunlop J. A cog in cognition: how the alpha 7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits. Pharmacol Ther 2009, 122:302-311.
72. Parikh V., Man K., Decker M.W., Sarter M. Glutamatergic contributions to nicotinic acetylcholine receptor agonist-evoked cholinergic transients in the prefrontal cortex. J Neurosci 2008, 28:3769-3780.
73. Picciotto M.R., Caldarone B.J., King S.L., Zachariou V. Nicotinic receptors in the brain: links between molecular biology and behavior. Neuropsychopharmacology 2000, 22:451-465.
74. Canal N., Imbimbo B.P. Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. Clin Pharmacol Ther 1996, 60:218-228.
75. Knoppman D. Pharmacotherapy for Alzheimer's disease. Curr Neurol Neurosci Rep 2001, 1:428-432.
76. Newman M.B., Arendash G.W., Shytle R.D., Bickford P.C., Tighe T., Sanberg P.R. Nicotine's oxidative and antioxidant properties in CNS. Life Sci 2002, 71:2807-2820.
77. Yildiz D., Ercal N., Armstrong D.W. Nicotine enantiomers and oxidative stress. Toxicology 1998, 130:155-165.
78. Yildiz D., Liu Y.S., Ercal N., Armstrong D.W. Comparison of pure nicotine- and smokeless tobacco extract-induced toxicities and oxidative stress. Arch Environ Contam Toxicol 1999, 37:434-439.
79. Wetscher G.J., Bagchi M., Bagchi D., Perdikis G., Hinder P.R., Glaser K., et al. Free radical production in nicotine treated pancreatic tissue. Free Radic Biol Med 1995, 18:877-882.
80. Helen A., Krishnakumar K., Vijayammal P.L., Augusti K.T. A comparative study of antioxidants S-allyl cysteine sulfoxide and vitamin E on the damages induced by nicotine in rats. Pharmacology 2003, 67:113-117.
81. Jain A., Dwivedi N., Bhargava R., Flora S.J. Silymarin and naringenin protects nicotine induced oxidative stress in young rats. Oxid Antioxid Med Sci 2012, 1:41-49.
82. Hamilton A., Holscher C. The effect of ageing on neurogenesis and oxidative stress in the APP(swe)/PS1(deltaE9) mouse model of Alzheimer's disease. Brain Res 2012, 1449:83-93.
83. Huang T.T., Zou Y., Corniola R. Oxidative stress and adult neurogenesis-effects of radiation and superoxide dismutase deficiency. Semin Cell Dev Biol 2012, 23:738-744.